Effect of DSP-4, a Noradrenergic Neurotoxin, on Sleep and Wakefulness and Sensitivity to Drugs Acting on Adrenergic Receptors in the Rat
Author(s) -
Jaime M. Monti,
Luisa D'Angelo,
Héctor Jantos,
Luis Barbeito,
Victoria Abó
Publication year - 1988
Publication title -
sleep
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.222
H-Index - 207
eISSN - 1550-9109
pISSN - 0161-8105
DOI - 10.1093/sleep/11.4.370
Subject(s) - yohimbine , methoxamine , wakefulness , endocrinology , neurotoxin , medicine , sleep (system call) , clonidine , prazosin , antagonist , receptor , agonist , biology , neuroscience , electroencephalography , computer science , operating system
DSP-4, a neurotoxin which produces a marked and long-lasting depletion of norepinephrine (NE) in the central nervous system, was given in a dose of 50 mg/kg by i.p. route to rats prepared for chronic sleep recordings. Light sleep was significantly increased and REM sleep decreased during the first 2 days following DSP-4. Thereafter, REM sleep showed a consistent increase which attained significance on days 5 and 6 postinjection, thus indicating a permissive role for NE on this behavioral state. We examined also whether pretreatment with DSP-4 would modify the effects of clonidine, yohimbine, methoxamine, or clenbuterol on sleep and wakefulness. The sensitivity to alpha 2-agents, methoxamine, and clenbuterol was respectively slightly increased or unchanged, decreased, and clearly increased after DSP-4.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom